Team-Based Care for Outpatients with Heart Failure

Heart Failure Clinics

Volumn 11, Issue 3, 2015, Pages 379-405

  Creaser, Julie W ^a   DePasquale, Eugene C ^a   Vandenbogaart, Elizabeth ^a   Rourke, Darlene ^a   Chaker, Tamara ^a   Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Advanced care options; Disease management; Multidisciplinary heart failure team; Outpatient heart failure medical therapy; Telemonitoring

Indexed keywords

DIGITALIS; DIGOXIN; DOBUTAMINE; ENALAPRIL; ENOXIMONE; INOTROPIC AGENT; MILRINONE; SACUBITRIL PLUS VALSARTAN; TOLVAPTAN;

ASSISTED CIRCULATION; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CONTROLLED CLINICAL TRIAL (TOPIC); DIETITIAN; DIURESIS; EVIDENCE BASED PRACTICE; EXERCISE; HEART FAILURE; HEMODYNAMIC MONITORING; HOME CARE; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NURSE; OUTPATIENT; OUTPATIENT CARE; PALLIATIVE THERAPY; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PHYSICIAN; PHYSIOTHERAPIST; PSYCHOLOGIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF CARE; SOCIAL WORKER; SYSTEMATIC REVIEW (TOPIC); TEAM BASED CARE; TEAMWORK; TELEMONITORING; AMBULATORY CARE; DISEASE MANAGEMENT; ECONOMICS; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROCEDURES; QUALITY OF LIFE;

AMBULATORY CARE; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; OUTPATIENTS; PATIENT CARE TEAM; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 84937435776     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2015.03.004     Document Type: Review

References (172)

1. Goldstein N.E., May C.W., Meier D.E. Comprehensive care for mechanical circulatory support: a new frontier for synergy with palliative care. Circ Heart Fail 2011, 4(4):519-527.
2. Banka G., Heidenreich P.A., Fonarow G.C. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. JAm Coll Cardiol 2013, 61(13):1440-1446.
3. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update. Circulation 2014, 129(3):e28-e292.
4. Thomas S.S., Smallwood J., Smith C.M., et al. Discharge outcomes in patients with paracorporeal biventricular assist devices. Ann Thorac Surg 2014, 97(3):894-900.
5. Gheorghiade M., Follath F., Ponikowski P., et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010, 12(5):423-433.
6. Braunschweig F., Cowie M.R., Auricchio A. What are the costs of heart failure?. Europace 2011, 13(Suppl 2):ii13-ii17.
7. Goldsmith S.R., Brandimarte F., Gheorghiade M. Congestion as a therapeutic target in acute heart failure syndromes. Prog Cardiovasc Dis 2010, 52(5):383-392.
8. Blair J.E., Pang P.S., Schrier R.W., et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 2011, 32(20):2563-2572.
9. Kim S.M., Han H.R. Evidence-based strategies to reduce readmission in patients with heart failure. JNurse Pract 2013, 9.
10. Valika A.A., Gheorghiade M. ACE inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature. Heart Fail Rev 2013, 18:135-140.
11. Stewart S. Heart failure management-a team based approach. Aust Fam Physician 2010, 39(12):894-896.
12. Vinson J.M., Rich M.W., Sperry J.C., et al. Early readmission of elderly patients with congestive heart failure. JAm Geriatr Soc 1990, 38(12):1290-1295.
13. Michalsen A., König G., Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998, 80(5):437-441.
14. Tsuyuki R.T., McKelvie R.S., Arnold J.M., et al. Acuteprecipitants of congestive heart failure exacerbations. Arch Intern Med 2001, 161(19):2337-2342.
15. Gustafsson F., Arnold J.M. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J 2004, 25(18):1596-1604.
16. Wagner E.H. The role of patient care teams in chronic disease management. BMJ 2000, 320(7234):569.
17. Institute of Medicine (US), Olsen L., Saunders R.S., et al. Patients charting the course 2011, 187-212. Wahington DC: National Academies Press.
18. Hauptman P.J., Rich M.W., Heidenreich P.A., et al. The heart failure clinic: a consensus statement of the Heart Failure Society of America. JCard Fail 2008, 14:801-815.
19. Bernard S. Disease management: a pharmaceutical industry perspective. Pharmaceutical Exec 1995, 15:48-50.
20. DePasquale E.C., Fonarow G.C. Apractical guide for reducing readmissions in heart failure. Heart failure: the expert's approach 2014, 183-192. Delhi: Jaypee Brothers Medical Publishers. A. Maisel, G. Filippatos (Eds.).
21. Krumholz H.M., Currie P.M., Riegel B., et al. Ataxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation 2006, 114(13):1432-1445.
22. Albert N.M., Fonarow G.C., Yancy C.W., et al. Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). Am J Cardiol 2010, 105(12):1773-1779.
23. Heart Failure Society of America, Lindenfeld J., Albert N.M., et al. HFSA 2010 comprehensive heart failure practice guideline. JCard Fail 2010, 16(6):e1-e194.
24. Adams K.F., Lindenfeld J., Arnold J., et al. HFSA 2006 comprehensive heart failure practice guideline. JCard Fail 2006, 12:e1-e119.
25. Cintron G., Bigas C., Linares E., et al. Nurse practitioner role in a chronic congestive heart failure clinic: in-hospital time, costs, and patient satisfaction. HeartLung 1983, 12(3):237-240.
26. Rich M.W., Beckham V., Wittenberg C., et al. Amultidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. NEngl J Med 1995, 333(18):1190-1195.
27. Rich M.W., Vinson J.M., Sperry J.C., et al. Prevention of readmission in elderly patients with congestive heart failure: results of a prospective, randomized pilot study. JGen Intern Med 1993, 8(11):585-590.
28. Howlett J.G. Specialist heart failure clinics must evolve to stay relevant. Can J Cardiol 2014, 30(3):276-280.
29. Lasater M. The effect of a nurse-managed CHF clinic on patient readmission and length of stay. Home Healthc Nurse 1996, 14(5):351-356.
30. Smith L.E., Fabbri S.A., Pai R., et al. Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. Clin Cardiol 1997, 20(11):949-954.
31. Cline C., Israelsson B., Willenheimer R.B., et al. Cost effective management programme for heart failure reduces hospitalisation. Heart 1998, 80(5):442-446.
32. Dahl J., Penque S. The effects of an advanced practice nurse-directed heart failure program. Nurse Pract 2000, 25(3):61-62. 65-8, 71-4 passim.
33. McDonald K., Ledwidge M., Cahill J., et al. Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. JCard Fail 2002, 8(3):142-148.
34. Atienza F., Anguita M., Martinez-Alzamora N., et al. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. Eur J Heart Fail 2004, 6(5):643-652.
35. Thompson D.R., Roebuck A., Stewart S. Effects of a nurse-led, clinic and home-based intervention on recurrent hospital use in chronic heart failure. Eur J Heart Fail 2005, 7(3):377-384.
36. Del Sindaco D., Pulignano G., Minardi G., et al. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure. JCardiovasc Med 2007, 8(5):324-329.
37. Jaarsma T., van der Wal M.H., Lesman-Leegte I., et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure. Arch Intern Med 2008, 168(3):316-324.
38. Clark R.A., Inglis S.C., McAlister F.A., et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ 2007, 334(7600):942.
39. Holland R. Systematic review of multidisciplinary interventions in heart failure. Heart 2005, 91(7):899-906.
40. Whellan D.J., Hasselblad V., Peterson E., et al. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J 2005, 149(4):722-729.
41. McAlister F.A., Stewart S., Ferrua S., et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. JAm Coll Cardiol 2004, 44(4):810-819.
42. Andrikopoulou E., Abbate K., Whellan D.J. Conceptual model for heart failure disease management. Can J Cardiol 2014, 30(3):304-311.
43. Jaarsma T. Inter-professional team approach to patients with heart failure. Heart 2005, 91(6):832-838.
44. Stewart S., Horowitz J.D. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation 2002, 105(24):2861-2866.
45. Doughty R.N., Wright S.P., Pearl A., et al. Randomized, controlled trial of integrated heart failure management: the Auckland Heart Failure Management Study. Eur Heart J 2002, 23(2):139-146.
46. Riegel B., Carlson B., Glaser D., et al. Which patients with heart failure respond best to multidisciplinary disease management?. JCard Fail 2000, 6(4):290-299.
47. Blue L., Lang E., McMurray J.J., et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ 2001, 323(7315):715-718.
48. Jaarsma T., Halfens R., Abu-Saad H., et al. Effects of education and support on self-care and resource utilization in patients with heart failure. Eur Heart J 1999, 20(9):673-682.
49. Kasper E.K., Gerstenblith G., Hefter G., et al. Arandomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. JAm Coll Cardiol 2002, 39(3):471-480.
50. Stewart S., Pearson S., Horowitz J.D. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med 1998, 158(10):1067-1072.
51. Stewart S., Marley J.E., Horowitz J.D. Effects of a multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999, 354(9184):1077-1083.
52. Stewart S., Vandenbroek A.J., Pearson S., et al. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999, 159(3):257-261.
53. Riegel B., Carlson B., Kopp Z., et al. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. Arch Intern Med 2002, 162(6):705-712.
54. Laramee A.S., Levinsky S.K., Sargent J., et al. Case management in a heterogeneous congestive heart failure population-a randomized controlled trial. Arch Intern Med 2003, 163(7):809-817.
55. Naylor M.D., Brooten D.A., Campbell R.L., et al. Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial. JAm Geriatr Soc 2004, 52(5):675-684.
56. Anderson C., Deepak B.V., Amoateng-Adjepong Y., et al. Benefits of comprehensive inpatient education and discharge planning combined with outpatient support in elderly patients with congestive heart failure. Congest Heart Fail 2005, 11(6):315-321.
57. Inglis S.C., Clark R.A., McAlister F.A., et al. Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: abridged Cochrane review. Eur J Heart Fail 2011, 13(9):1028-1040.
58. Savard L.A., Thompson D.R., Clark A.M. Ameta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials 2011, 12:194.
59. Grady K.L., Dracup K., Kennedy G., et al. Team management of patients with heart failure: a statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association. Circulation 2000, 102(19):2443-2456.
60. Hanumanthu S., Butler J., Chomsky D., et al. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation 1997, 96(9):2842-2848.
61. Fonarow G.C., Stevenson L.W., Walden J.A., et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. JAm Coll Cardiol 1997, 30(3):725-732.
62. Milfred-Laforest S.K., Chow S.L., Didomenico R.J., et al. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. JCard Fail 2013, 19(5):354-369.
63. Eggink R.N., Lenderink A.W., Widdershoven J.W., et al. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci 2010, 32(6):759-766.
64. LaForest S., Gee J., Pugacz A., et al. SERIOUS medication reconciliation clinic: improving transitions of care. JCard Fail 2010, 16:112m.
65. Murray M.D., Young J., Hoke S., et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med 2007, 146(10):714-725.
66. Rodgers J.E., Stough W.G. Underutilization of evidence-based therapies in heart failure: the pharmacist's role. Pharmacotherapy 2007, 27(4 Pt 2):18S-28S.
67. Campbell P.T., Tremaglio J., Bhardwaj A., et al. Utility of daily diuretic orders for identifying acute decompensated heart failure patients for quality improvement. Crit Pathw Cardiol 2010, 9(3):148-151.
68. Cheng J.W., Cooke-Ariel H. Pharmacists' role in the care of patients with heart failure: review and future evolution. JManag Care Pharm 2014, 20(2):206-213.
69. Gattis W.A., Hasselblad V., Whellan D.J., et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med 1999, 159(16):1939-1945.
70. Koshman S.L., Charrois T.L., Simpson S.H., et al. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med 2008, 168(7):687-694.
71. Arcand J.A., Brazel S., Joliffe C., et al. Education by adietitian in patients with heart failure results in improved adherence with a sodium-restricted diet: a randomized trial. Am Heart J 2005, 150(4):716.
72. O'Connor C.M., Whellan D.J., Lee K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301(14):1439-1450.
73. Flynn K.E., Piña I.L., Whellan D.J., et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301(14):1451-1459.
74. Decision Memo for Cardiac Rehabilitation (CR)Programs-Chronic heart failure (CAG-00437N). cmsgov. Available at: . Accessed November 11, 2014. http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=270.
75. Rees K., Bennett P., West R., et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2004, (2). CD002902.
76. Child A., Sanders J., Sigel P., et al. Meeting the psychological needs of cardiac patients: an integrated stepped-care approach within a cardiac rehabilitation setting. Br J Cardiol 2010, 17.
77. Linden W., Phillips M.J., Leclerc J. Psychological treatment of cardiac patients: a meta-analysis. Eur Heart J 2007, 28(24):2972-2984.
78. Fonarow G.C., Abraham W.T., Albert N.M., et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008, 168(8):847-854.
79. Klersy C., De Silvestri A., Gabutti G., et al. Ameta-analysis of remote monitoring of heart failure patients. JAm Coll Cardiol 2009, 54(18):1683-1694.
80. Inglis S.C., Clark R.A., McAlister F.A., et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev 2010, (8). CD007228. Inglis SC, editor.
81. Chaudhry S.I., Mattera J.A., Curtis J.P., et al. Telemonitoring in patients with heart failure. NEngl J Med 2010, 363(24):2301-2309.
82. Koehler F.F., Winkler S.S., Schieber M.M., et al. Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail 2010, 12(12):1354-1362.
83. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 62(16):e147-e239.
84. Whellan D.J., Sarkar S., Koehler J., et al. Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. Am J Cardiol 2013, 111(1):79-84.
85. Ypenburg C., Bax J.J., van der Wall E.E., et al. Intrathoracic impedance monitoring to predict decompensated heart failure. Am J Cardiol 2007, 99(4):554-557.
86. Abraham W.T., Adamson P.B., Bourge R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011, 377(9766):658-666.
87. Adamson P.B., Abraham W.T., Bourge R.C., et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014, 7(6):935-944.
88. Gheorghiade M.M., Pang P.S., Ambrosy A.P., et al. Acomprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 2012, 17(3):485-509.
89. Fonarow G.C., Abraham W.T., Albert N.M., et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007, 297(1):61-70.
90. Hernandez A.F., Fonarow G.C., Liang L., et al. The need for multiple measures of hospital quality: results from the Get with the Guidelines-Heart Failure Registry of the American Heart Association. Circulation 2011, 124(6):712-719.
91. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. NEngl J Med 2011, 364(9):797-805.
92. Cleland J.G., McGowan J., Clark A., et al. The evidence for beta blockers in heart failure. BMJ 1999, 318(7187):824-825.
93. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. NEngl J Med 2001, 344(22):1651-1658.
94. Schrier R.W., Gheorghiade M. Challenge of rehospitalizations for heart failure: potential of natriuretic doses of mineralocorticoid receptor antagonists. Am Heart J 2011, 161(2):221-223.
95. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. NEngl J Med 1992, 327(10):685-691.
96. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364:11-21.
97. Jong P., Demers C., McKelvie R.S., et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. JAm Coll Cardiol 2002, 39(3):463-470.
98. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355(9215):1582-1587.
99. Gheorghiade M., Konstam M.A., Burnett J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297(12):1332-1343.
100. Schrier R.W., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. NEngl J Med 2006, 355(20):2099-2112.
101. Albert N.M., Yancy C.W., Liang L., et al. Use of aldosterone antagonists in heart failure. JAMA 2009, 302(15):1658-1665.
102. Fonarow G.C., Abraham W.T., Albert N.M., et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure results of the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Arch Intern Med 2007, 167(14):1493-1502.
103. Allen L.A., Stevenson L.W., Grady K.L., et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012, 125(15):1928-1952.
104. Casarett D., Pickard A., Bailey F.A., et al. Do palliative consultations improve patient outcomes?. JAm Geriatr Soc 2008, 56(4):593-599.
105. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEngl J Med 2004, 351(20):2049-2057.
106. Morrison R.S., Penrod J.D., Cassel J.B., et al. Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med 2008, 168(16):1783-1790.
107. Norton S.A., Hogan L.A., Holloway R.G., et al. Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients. Crit Care Med 2007, 35(6):1530-1535.
108. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. NEngl J Med 1997, 336(8):525-533.
109. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114(5):397-403.
110. Bruce C.R. Areview of ethical considerations for ventricular assist device placement in older adults. Aging Dis 2013, 4(2):100-112.
111. Bourge R.C., Fleg J.L., Fonarow G.C., et al. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med 2013, 126(8):701-708.
112. Ahmed A., Bourge R.C., Fonarow G.C., et al. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med 2014, 127(1):61-70.
113. Hashim T., Elbaz S., Patel K., et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med 2014, 127(2):132-139.
114. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. NEngl J Med 2014, 371(11):993-1004.
115. Hernandez A.F., Mi X., Hammill B.G., et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 2012, 308(20):2097-2107.
116. Califf R.M., Vidaillet H., Goldman L. Advanced congestive heart failure: what do patients want?. Am Heart J 1998, 135(6 Pt 2 Su):S320-S326.
117. Stanek E.J., Oates M.B., McGhan W.F., et al. Preferences for treatment outcomes in patients with heart failure: symptoms versus survival. JCard Fail 2000, 6:225-232.
118. Dev S., Clare R.M., Felker G.M., et al. Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure. Eur J Heart Fail 2012, 14(1):45-53.
119. Lewis E.F., Johnson P.A., Johnson W., et al. Preferences for quality of life or survival expressed by patients with heart failure. JHeart Lung Transplant 2001, 20(9):1016-1024.
120. MacIver J., Rao V., Delgado D.H., et al. Choices: a study of preferences for end-of-life treatments in patients with advanced heart failure. JHeart Lung Transplant 2008, 27(9):1002-1007.
121. Yancy C.W., Burnett J.C., Fonarow G.C., et al. Decompensated heart failure: is there a role for the outpatient use of nesiritide?. Congest Heart Fail 2004, 10(5):230-236.
122. Felker G.M., O'Connor C.M., Braunwald E. Heart failure clinical research network investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circ Heart Fail 2009, 2(1):56-62.
123. Emerman C.L., Demarco T., Costanzo M.R., et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE(R) Registry. JCard Fail 2004, 10(4):S116.
124. Hebert K.K., Dias A.A., Franco E.E., et al. Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program. Congest Heart Fail 2011, 17(6):309-313.
125. Yancy C.W., Krum H., Massie B.M., et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail 2008, 1(1):9-16.
126. Ryder M., Murphy N.F., McCaffrey D., et al. Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail 2008, 10(3):267-272.
127. Lazkani M., Ota K.S. The role of outpatient intravenous diuretic therapy in a transitional care program for patients with heart failure: a case series. JClin Med Res 2012, 4(6):434-438.
128. Zacharias H., Raw J., Nunn A., et al. Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure?. Palliat Med 2011, 25(6):658-663.
129. Banerjee P., Tanner G., Williams L. Intravenous diuretic day-care treatment for patients with heart failure. Clin Med 2012, 12(2):133-136.
130. Costanzo M.R., Mills R.M., Wynne J. Characteristics of "Stage D" heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). Am Heart J 2008, 155(2):339-347.
131. Adler E.D., Goldfinger J.Z., Kalman J., et al. Palliative care in the treatment of advanced heart failure. Circulation 2009, 120(25):2597-2606.
132. Follath F., Yilmaz M.B., Delgado J.F., et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 2011, 37(4):619-626.
133. Guglin M., Kaufman M. Inotropes do not increase mortality in advanced heart failure. Int J Gen Med 2014, 7:237-251.
134. Stevenson L.W. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation 2003, 108(4):492-497.
135. Francis G.S., Bartos J.A., Adatya S. Inotropes. JAm Coll Cardiol 2014, 63(20):2069-2078.
136. Hershberger R.E., Nauman D., Walker T.L., et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. JCard Fail 2003, 9(3):180-187.
137. Lyons M.G., Carey L. Parenteral inotropic therapy in the home: an update for home care and hospice. Home Healthc Nurse 2013, 31(4):190-206.
138. Cowley A.J., Skene A.M. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Br Heart J 1994, 72(3):226-230.
139. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. NEngl J Med 1991, 325(21):1468-1475.
140. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray?. JAm Coll Cardiol 1993, 22(4 Suppl A):119A-126A.
141. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. Adose-dependent increase in mortality with vesnarinone among patients with severe heart failure. NEngl J Med 1998, 339(25):1810-1816.
142. Dies F., Krell M., Whitlow P. Intermittent, ambulatory dobutamine infusion in severe chronic cardiac failure. Br J Clin Pract 1986, 45:37-40.
143. Oliva F., Latini R., Politi A., et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999, 138(2 Pt 1):247-253.
144. Miller L.W., Merkle E.J., Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 1990, 18(1 Pt 2):S30-S33.
145. Canver C.C., Chanda J. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. Ann Thorac Surg 2000, 69(6):1823-1826.
146. Brozena S.C., Twomey C., Goldberg L.R., et al. Aprospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. JHeart Lung Transplant 2004, 23(9):1082-1086.
147. Upadya S., Lee F.A., Saldarriaga C., et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. JHeart Lung Transplant 2004, 23(4):466-472.
148. Sindone A.P., Keogh A.M., Macdonald P.S., et al. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J 1997, 134(5 Pt 1):899-900.
149. Harjai K.J., Mehra M.R., Ventura H.O., et al. Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes. Chest 1997, 112(5):1298-1303.
150. Hauptman P.J., Mikolajczak P., George A., et al. Chronic inotropic therapy in end-stage heart failure. Am Heart J 2006, 152(6):1096.e1-1096.e8.
151. Gorodeski E.Z., Chu E.C., Reese J.R., et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail 2009, 2(4):320-324.
152. Assad-Kottner C., Chen D., Jahanyar J., et al. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times. JCard Fail 2008, 14(10):839-843.
153. Meaux N. Home infusion of inotropic therapy for patients with advanced heart failure. Infusion 2012.
154. Rogers J.G., Milano C.A. Ramping up evidence-based ventricular assist device care. J Am Coll Cardiol 2012, 1-2. 10.1016/j.jacc.2012.08.978.
155. Demondion P., Fournel L., Niculescu M., et al. The challenge of home discharge with a total artificial heart: the La Pitie Salpetriere experience. European Journal of Cardio-Thoracic Surgery 2013, 44(5):843-848.
156. Kirklin J.K., Naftel D.C., Kormos R.L., et al. Fifth INTERMACS annual report Risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 2013, 32(2):141-156.
157. Kirklin J.K., Naftel D.C., Pagani F.D., et al. Sixth INTERMACS annual report: a 10,000-patient database. JHeart Lung Transplant 2014, 33(6):555-564.
158. Creaser J.W., Rourke D., Vandenbogaart E., et al. Outcomes of biventricular mechanical support patients discharged to home to await heart transplantation. J Cardiovasc Nurs 2014, 10.1097/JCN.0000000000000168.
159. Jaroszewski D.E., Anderson E.M., Pierce C.N., et al. The SynCardia freedom driver: a portable driver for discharge home with the total artificial heart. JHeart Lung Transplant 2011, 30(7):844-845.
160. El-Banayosy A., Kizner L., Arusoglu L., et al. Home discharge and out-of-hospital follow-up of total artificial heart patients supported by a portable driver system. ASAIO J 2014, 60(2):148-153.
161. Dew M.A., Kormos R.L., Winowich S., et al. Quality of life outcomes in left ventricular assist system inpatients and outpatients. ASAIO J 1999, 45(3):218-225.
162. Kwok T., Lee J., Woo J., et al. A randomized controlled trial of a community nurse-supported hospital discharge programme in older patients with chronic heart failure. J Clin Nurs 2008, 17(1):109-117.
163. Göhler A., Januzzi J.L., Worrell S.S., et al. A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Card Fail 2006, 12(7):554-567.
164. Jovicic A., Holroyd-Leduc J.M., Straus S.E. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord 2006, 6:43.
165. Kim Y.-J., Soeken K.L. A meta-analysis of the effect of hospital-based case management on hospital length-of-stay and readmission. Nurs Res 2005, 54(4):255-264.
166. Phillips C.O., Singa R.M., Rubin H.R., et al. Complexity of program and clinical outcomes of heart failure disease management incorporating specialist nurse-led heart failure clinics - a meta-regression analysis. Eur J Heart Fail 2005, 7(3):9.
167. Roccaforte R., Demers C., Baldassarre F., et al. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. a meta-analysis. Eur J Heart Fail 2005, 7(7):1133-1144.
168. Taylor S, Bestall J, Cotter S, et al. Clinical service organisation for heart failure. Taylor SJ, ed. Cochrane Database Syst Rev. 2005;(2):CD002752-CD002752. http://dx.doi.org/10.1002/14651858.CD002752.pub2.
169. Gonseth J., Guallar-Castillón P., Banegas J.R., et al. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J 2004, 25(18):1570-1595.
170. Gwadry-Sridhar F.H., Flintoft V., Lee D.S., et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004, 164(21):2315-2320.
171. Phillips C.O., Wright S.M., Kern D.E., et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004, 291(11):1358-1367.
172. McAlister F.A., Lawson F.M., Teo K.K., et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001, 110(5):378-384.